JP2020132638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020132638A5 JP2020132638A5 JP2020022548A JP2020022548A JP2020132638A5 JP 2020132638 A5 JP2020132638 A5 JP 2020132638A5 JP 2020022548 A JP2020022548 A JP 2020022548A JP 2020022548 A JP2020022548 A JP 2020022548A JP 2020132638 A5 JP2020132638 A5 JP 2020132638A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- cancer
- anticancer
- group
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001093 anti-cancer Effects 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 25
- 239000000611 antibody drug conjugate Substances 0.000 claims 11
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 229940043355 kinase inhibitor Drugs 0.000 claims 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 3
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 229940100198 alkylating agent Drugs 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 230000008512 biological response Effects 0.000 claims 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 230000004481 post-translational protein modification Effects 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 229960004669 basiliximab Drugs 0.000 claims 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 229960003227 afelimomab Drugs 0.000 claims 1
- 229960004539 alirocumab Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229950001537 amatuximab Drugs 0.000 claims 1
- 229950005794 anrukinzumab Drugs 0.000 claims 1
- 229950003145 apolizumab Drugs 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950005122 atinumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229940075127 azintuxizumab Drugs 0.000 claims 1
- 229960004965 begelomab Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229950000321 benralizumab Drugs 0.000 claims 1
- 229950010559 besilesomab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229950008086 bezlotoxumab Drugs 0.000 claims 1
- 229950006326 bimagrumab Drugs 0.000 claims 1
- 229950002853 bimekizumab Drugs 0.000 claims 1
- 229950000009 bleselumab Drugs 0.000 claims 1
- 229960003008 blinatumomab Drugs 0.000 claims 1
- 229950011350 bococizumab Drugs 0.000 claims 1
- 229960002874 briakinumab Drugs 0.000 claims 1
- 229960003735 brodalumab Drugs 0.000 claims 1
- 229950000025 brolucizumab Drugs 0.000 claims 1
- 229950009653 camidanlumab Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229950009658 cofetuzumab Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229950008962 detumomab Drugs 0.000 claims 1
- 229950006723 dezamizumab Drugs 0.000 claims 1
- 229960004497 dinutuximab Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229950011453 dusigitumab Drugs 0.000 claims 1
- 229940057045 duvortuxizumab Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960001776 edrecolomab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 229950002209 efungumab Drugs 0.000 claims 1
- 229940096918 enapotamab Drugs 0.000 claims 1
- 229950009760 epratuzumab Drugs 0.000 claims 1
- 229950006063 eptinezumab Drugs 0.000 claims 1
- 229950001616 erenumab Drugs 0.000 claims 1
- 229950008579 ertumaxomab Drugs 0.000 claims 1
- 229950004912 etrolizumab Drugs 0.000 claims 1
- 229960002027 evolocumab Drugs 0.000 claims 1
- 229950001488 faralimomab Drugs 0.000 claims 1
- 229950009929 farletuzumab Drugs 0.000 claims 1
- 229950010512 fezakinumab Drugs 0.000 claims 1
- 229950002846 ficlatuzumab Drugs 0.000 claims 1
- 229950008085 figitumumab Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 229950000918 glembatumumab Drugs 0.000 claims 1
- 229950000518 labetuzumab Drugs 0.000 claims 1
- 229950001813 laprituximab Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950007243 mirvetuximab Drugs 0.000 claims 1
- 229950001907 monalizumab Drugs 0.000 claims 1
- 229960001521 motavizumab Drugs 0.000 claims 1
- 229950007708 namilumab Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229950005790 navicixizumab Drugs 0.000 claims 1
- 229950010591 navivumab Drugs 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229950009007 orticumab Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229950005380 rosmantuzumab Drugs 0.000 claims 1
- 229950005374 ruplizumab Drugs 0.000 claims 1
- 229950000106 samalizumab Drugs 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 229940060041 satralizumab Drugs 0.000 claims 1
- 229950007308 satumomab Drugs 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- 229960003323 siltuximab Drugs 0.000 claims 1
- 229950009513 simtuzumab Drugs 0.000 claims 1
- 229950003804 siplizumab Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229950004742 tigatuzumab Drugs 0.000 claims 1
- 229950005515 tildrakizumab Drugs 0.000 claims 1
- 229950006757 timolumab Drugs 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229950008836 tosatoxumab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229950000835 tralokinumab Drugs 0.000 claims 1
- 229950010086 tregalizumab Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229950005972 urelumab Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229950004362 urtoxazumab Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 229950003520 utomilumab Drugs 0.000 claims 1
- 229950000449 vanucizumab Drugs 0.000 claims 1
- 229950002148 vatelizumab Drugs 0.000 claims 1
- 229960004914 vedolizumab Drugs 0.000 claims 1
- 229950000815 veltuzumab Drugs 0.000 claims 1
- 229950009002 zanolimumab Drugs 0.000 claims 1
- 229950009083 ziralimumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019023972 | 2019-02-13 | ||
| JP2019023972 | 2019-02-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020132638A JP2020132638A (ja) | 2020-08-31 |
| JP2020132638A5 true JP2020132638A5 (zh) | 2022-12-28 |
Family
ID=72262311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020022548A Pending JP2020132638A (ja) | 2019-02-13 | 2020-02-13 | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2020132638A (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115286820B (zh) * | 2022-10-10 | 2022-12-16 | 佛山科学技术学院 | 一种光交联胶原基水凝胶及其制备方法和应用 |
-
2020
- 2020-02-13 JP JP2020022548A patent/JP2020132638A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11407801B2 (en) | SIRP-gamma polypeptide compositions and treatment of cancer | |
| AU2011257219B2 (en) | Stable multi-dose compositions comprising an antibody and a preservative | |
| US11466158B2 (en) | Phthalocyanine dye compounds, conjugates and methods of use thereof | |
| JPWO2019031614A5 (zh) | ||
| TWI805602B (zh) | 包含半星芒體衍生物之抗體藥物複合體 | |
| US20190162718A1 (en) | A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples | |
| JP2022191210A5 (zh) | ||
| JPWO2020166592A5 (zh) | ||
| ES2954580T3 (es) | Medicamento conjugado que incluye derivados de quinolina | |
| US20220152216A1 (en) | Antibody-polymer conjugates | |
| JP2020132638A5 (zh) | ||
| AU2021247685A1 (en) | Conjugates | |
| WO2021206160A1 (ja) | 抗体薬物複合体 | |
| JP7479302B2 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
| JP2022513517A (ja) | 癌の処置又は予防において使用する為のキノリン誘導体 | |
| JP2016539129A5 (zh) | ||
| US20170267753A1 (en) | Combination therapy for co-administration of monoclonal antibodies | |
| WO2024078449A1 (en) | Compounds, compositions and methods | |
| EP4319817A1 (en) | Phthalocyanine dye compounds, conjugates and methods of use thereof | |
| WO2024003002A1 (en) | N-substituted indole derivatives and conjugates for the treatment of cancer |